TARDBP and amyotrophic lateral sclerosis: A novel approach using ASO therapy aims to increase Stathmin5 expression in sALS patients, enhancing nuclear TDP-43 content and counteracting TDP-43 nuclear depletion, a hallmark of ALS pathology.